AATHEN is pleased to announce seed funding for PIs and trainees interested in testing ARBs, analogues and biomarkers in non-hypertensive or non-AngII-driven settings. Since AATHEN is at an early stage of its growth, funding for the first year is limited to $3,000 per PI (preferably trainee or staff salary, as approved by UBC VP Research; no consumables).
See form attached: Project Form AATHEN
Once the form is completed, you can send it to : angiotensin.thera@ubc.ca